Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2014CG123 Principal Investigator Gordon, Peter
Phase Phase III
Age Group Both Scope National
Secondary Protocol No. AALL1331
Title MT2016-21 : COG AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) "AALL1331 - Amgen, Inc."
Applicable Disease Sites Lymphoid Leukemia
Drugs Involved 6-MERCAPTOPURINE (6-MP, PURINETHOL)
6-THIOGUANINE (6-TG)
ASPARAGINASE
Blinatumomab (AMG103)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
CYTARABINE (ARA-C, CYTOSINE ARABINOSIDE, CYTOSAR-U)
DEXAMETHASONE (DECADRON)
ETOPOSIDE (VP-16)
HYDROCORTISONE
LEUCOVORIN CALCIUM (CITROVORUM FACTOR, FOLINIC ACID)
METHOTREXATE
MITOXANTRONE
Pegaspargase
VINCRISTINE (ONCOVIN)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Jamie Walski Phone:
Email:wals0183@umn.edu